See more : Cencora (0HF3.L) Income Statement Analysis – Financial Results
Complete financial analysis of NovAccess Global Inc. (XSNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NovAccess Global Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Flowserve Corporation (0IQE.L) Income Statement Analysis – Financial Results
- Ashapuri Gold Ornament Limited (AGOL.BO) Income Statement Analysis – Financial Results
- Joindre Capital Services Limited (JOINDRE.BO) Income Statement Analysis – Financial Results
- China High Speed Transmission Equipment Group Co., Ltd. (0658.HK) Income Statement Analysis – Financial Results
- Franklin BSP Realty Trust, Inc. (FBRT) Income Statement Analysis – Financial Results
NovAccess Global Inc. (XSNX)
About NovAccess Global Inc.
NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. The company specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. NovAccess Global Inc. was incorporated in 1997 and is headquartered in Chesterland, Ohio.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.61M | 665.02K | 1.17M | 750.56K | 1.22M | 393.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.88K | 8.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 856.17K | 438.69K | 791.41K | 474.03K | 912.40K | 283.22K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 752.56K | 226.32K | 381.56K | 276.53K | 303.23K | 110.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.88K | 8.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 46.78% | 34.03% | 32.53% | 36.84% | 24.94% | 28.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 154.36K | 186.12K | 146.09K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 426.37K | 122.67K | 282.49K | 293.00K | 3.32M | 0.00 | 435.53K | 949.47K | 501.42K | 129.49K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 428.34K | 453.24K | 482.78K | 520.80K | 527.93K | 532.62K | 645.55K | 946.46K | 1.47M | 3.32M | 4.00M | 2.09M | 2.33M | 859.57K | 1.40M | 145.85K | 47.30K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.57K | 9.05K | 3.98K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.31M | 1.18M | 2.70M | 828.89K | 544.70K | 428.34K | 453.24K | 482.78K | 520.80K | 527.93K | 532.62K | 645.55K | 946.46K | 1.47M | 3.32M | 4.00M | 2.13M | 2.34M | 863.55K | 1.40M | 145.85K | 47.30K | 16.64K |
| Other Expenses | 0.00 | -961.00K | 16.22K | -5.09M | 580.00 | 280.00 | 164.00 | 1.60K | 4.65K | 14.73K | 34.94K | 41.71K | 38.47K | 86.95K | 661.81K | 257.22K | 77.25K | 82.94K | 18.44K | 0.00 | 0.00 | 0.00 | 348.00 |
| Operating Expenses | 2.47M | 1.37M | 2.70M | 828.89K | 545.28K | 428.62K | 453.40K | 484.38K | 525.45K | 542.66K | 993.93K | 809.93K | 1.27M | 1.85M | 3.98M | 4.26M | 2.65M | 3.38M | 1.38M | 1.53M | 145.85K | 47.30K | 16.99K |
| Cost & Expenses | 2.47M | 1.37M | 2.70M | 828.89K | 1.40M | 867.31K | 1.24M | 958.41K | 1.44M | 825.88K | 993.93K | 809.93K | 1.27M | 1.85M | 3.98M | 4.26M | 2.65M | 3.38M | 1.38M | 1.53M | 145.85K | 47.30K | 16.99K |
| Interest Income | 0.00 | 1.69K | 377.87 | 30.54 | 71.98 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.00 | 5.44K | 176.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.22M | 1.69M | 377.87K | 30.54K | 71.98K | 110.97K | 38.00K | 103.76K | 216.11K | 758.91K | 1.05M | 343.69K | 46.22K | 45.72K | 4.30K | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.47M | 1.37M | 2.70M | 580.00 | 580.00 | 280.00 | 164.00 | 1.60K | 4.65K | 14.73K | 34.94K | 41.71K | 38.47K | 86.95K | 127.29K | 257.22K | 77.25K | 82.94K | 18.44K | -19.38K | 0.00 | 0.00 | 348.00 |
| EBITDA | -1.03M | 0.00 | 0.00 | -6.96M | -544.12K | -202.01K | -71.68K | -137.50K | -1.08M | -1.18M | -958.00K | -1.26M | -1.03M | -2.08M | -10.50M | -3.80M | -1.83M | -3.28M | -1.36M | -1.55M | -145.85K | -47.30K | -354.53K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 12.92% | -30.38% | -6.11% | -27.48% | -19.71% | -106.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -53,245.03% | -41,013.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.47M | -1.37M | -2.70M | -828.89K | 207.28K | -202.29K | -71.84K | -207.86K | -222.22K | -432.36K | -992.93K | -809.93K | -1.27M | -1.85M | -3.98M | -4.26M | -2.64M | -3.37M | -1.38M | -1.53M | -145.85K | -47.30K | -16.99K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 12.88% | -30.42% | -6.12% | -27.69% | -18.28% | -109.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -38,379.45% | -42,098.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.26M | -348.31K | 186.47K | -6.16M | 2.14M | -3.77M | -426.82K | -35.01K | -1.10M | -1.52M | -1.53M | -745.27K | 149.77K | -359.93K | -6.66M | 203.24K | 671.66K | -74.03K | -17.43K | 19.38K | 0.00 | 0.00 | 337.89K |
| Income Before Tax | -4.72M | -1.72M | -2.51M | -6.99M | 2.34M | -3.97M | -498.66K | -242.87K | -1.32M | -1.95M | -2.52M | -1.56M | -1.12M | -2.21M | -10.63M | -4.23M | -1.54M | -3.37M | 0.00 | -1.51M | 0.00 | 0.00 | 320.90K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 145.70% | -596.89% | -42.51% | -32.36% | -108.64% | -495.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -22,391.08% | -42,147.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.31M | 377.87K | -190.72K | 71.98K | -3.66M | 38.00K | 103.76K | 216.11K | 758.91K | 1.05M | 343.69K | 46.22K | 45.72K | 6.66M | -203.24K | -1.35M | 74.03K | 17.43K | 652.00 | 145.87K | 47.30K | -322.48K |
| Net Income | -4.77M | 591.19K | -2.89M | -6.80M | 2.34M | -3.97M | -498.66K | -242.87K | -1.32M | -1.95M | -2.52M | -1.56M | -1.12M | -2.21M | -10.63M | -4.06M | -1.29M | -3.44M | -1.40M | -1.51M | -145.87K | -47.30K | 305.49K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 145.70% | -596.89% | -42.51% | -32.36% | -108.64% | -495.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,742.69% | -43,024.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.23 | 0.04 | -0.26 | -4.24 | 1.50K | -2.93 | -0.54 | -0.33 | -2.03 | -3.64 | -7.34 | -6.27 | -5.11 | -10.81 | -56.13 | -24.31 | -9.34 | -27.79 | -11.31 | -13.23 | -22.10 | -61.58 | 397.77 |
| EPS Diluted | -0.23 | 0.04 | -0.26 | -4.24 | 468.75 | -2.93 | -0.54 | -0.33 | -2.03 | -3.64 | -7.34 | -6.27 | -5.11 | -10.81 | -56.13 | -24.31 | -9.34 | -27.79 | -11.31 | -13.23 | -22.10 | -61.58 | 397.77 |
| Weighted Avg Shares Out | 20.74M | 16.53M | 11.26M | 1.60M | 1.56K | 1.35M | 930.96K | 733.54K | 649.71K | 535.80K | 343.57K | 247.86K | 218.62K | 204.44K | 189.46K | 167.00K | 138.01K | 123.85K | 123.85K | 114.04K | 6.60K | 768.00 | 768.00 |
| Weighted Avg Shares Out (Dil) | 20.83M | 16.53M | 11.26M | 1.60M | 5.00K | 1.35M | 930.96K | 733.54K | 649.71K | 535.80K | 343.57K | 247.86K | 218.62K | 204.44K | 189.46K | 167.00K | 138.01K | 123.85K | 123.85K | 114.04K | 6.60K | 768.00 | 768.00 |
NovAccess Global Advisory on Annual Meeting of Shareholders
CLEVELAND, OH / ACCESSWIRE / May 7, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its Annual Meeting of Shareholder which was previously scheduled to be held...
NovAccess Global Announces New License to Advance its Immunotherapy Platform
CLEVELAND, OH / ACCESSWIRE / April 30, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel immunotherapy for patients suffering from cancers of the central nervous system, today announced the procurement of a new intellectual property license...
NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders
CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business developments, financing and the 2024 annual meeting. The previously disclosed $10.7...
NovAccess Global Announces $10.7 Million Financing
Establishes Strong Financial Base To Advance Development of Novel Cancer Immunotherapies CLEVELAND, OH / ACCESSWIRE / January 2, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced it entered into a...
NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit
Cleveland, Ohio--(Newsfile Corp. - December 1, 2023) - NovAccess Global Inc. (OTCQB: XSNX) announced today it will be presenting at the December 7th, 2023 virtual Investor Summit. Event: December 7th Investor Summit Presentation: December 7th, 2023 @ 1:30 PM ET...
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
CLEVELAND, OH / ACCESSWIRE / November 10, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a preclinical biomedical company developing novel immunotherapies for brain tumor patients, today announced the appointment of Dr. Roscoe M. Moore, Jr., to its Scientific Advisory Board.
NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform
Development Begins on Fourth Generation of Primary Drug TLR-AD1 Targeting CNS Tumors Potential for Improved Outcomes for Cancer Patients in the $100 Billion a Year Immune Oncology Market CLEVELAND, OH / ACCESSWIRE / July 27, 2023 / NovAccess Global Inc....
NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
CLEVELAND, OH / ACCESSWIRE / July 13, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its Chief Executive Officer Dr. Dwain K. Irvin will be participating in the National...
NovAccess Global to Present at World Orphan Drug Congress
CLEVELAND, OH / ACCESSWIRE / February 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its CEO Dr. Dwain Irvin has been invited to present at the World Orphan...
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
Dr. Christopher Wheeler, NovAccess Lead Scientist, to Receive Leadership Award for his Contributions CLEVELAND, OH / ACCESSWIRE / February 3, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its...
Source: https://incomestatements.info
Category: Stock Reports